Nuveen
ANAB icon

Nuveen’s AnaptysBio ANAB Stock Holding History

Nuveen’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4M Buy
420,664
+104,599
+33% +$6.34M 0.01% 1040
2026
Q1 		$17.5M Sell
316,065
-620
-0.2% -$33.4K ﹤0.01% 1215
2025
Q4 		$15.4M Sell
316,685
-22,586
-7% -$880K ﹤0.01% 1299
2025
Q3 		$10.4M Buy
339,271
+15,737
+5% +$361K ﹤0.01% 1527
2025
Q2 		$7.18M Buy
323,534
+267,522
+478% +$5.6M ﹤0.01% 1703
2025
Q1 		$1.04M Hold
56,012
– – ﹤0.01% 2630
2024
Q4 		$742K Hold
56,012
– – ﹤0.01% 2831
2024
Q3 		$1.88M Hold
56,012
– – ﹤0.01% 2441
2024
Q2 		$1.4M Sell
56,012
-8,228
-13% -$192K ﹤0.01% 2558
2024
Q1 		$1.45M Buy
64,240
+11,126
+21% +$263K ﹤0.01% 2542
2023
Q4 		$1.14M Sell
53,114
-19,452
-27% -$336K ﹤0.01% 2677
2023
Q3 		$1.3M Buy
72,566
+159
+0.2% +$3.03K ﹤0.01% 2465
2023
Q2 		$1.47M Sell
72,407
-3,808
-5% -$77.2K ﹤0.01% 2488
2023
Q1 		$1.66M Sell
76,215
-83,479
-52% -$2.03M ﹤0.01% 2416
2022
Q4 		$4.95M Sell
159,694
-68,088
-30% -$1.92M ﹤0.01% 1908
2022
Q3 		$5.81M Sell
227,782
-24,022
-10% -$563K ﹤0.01% 1815
2022
Q2 		$5.11M Sell
251,804
-160,843
-39% -$3.56M ﹤0.01% 1919
2022
Q1 		$10.9M Sell
412,647
-484
-0.1% -$14.6K ﹤0.01% 1582
2021
Q4 		$14.4M Sell
413,131
-7,818
-2% -$248K ﹤0.01% 1449
2021
Q3 		$11.4M Buy
420,949
+12,593
+3% +$320K ﹤0.01% 1688
2021
Q2 		$10.6M Buy
408,356
+30,649
+8% +$735K ﹤0.01% 1832
2021
Q1 		$8.14M Buy
377,707
+220,383
+140% +$5.56M ﹤0.01% 1910
2020
Q4 		$3.38M Sell
157,324
-68,280
-30% -$1.66M ﹤0.01% 2254
2020
Q3 		$3.33M Sell
225,604
-5,539
-2% -$99.9K ﹤0.01% 2129
2020
Q2 		$5.16M Buy
231,143
+7,538
+3% +$138K ﹤0.01% 1881
2020
Q1 		$3.16M Buy
223,605
+30,128
+16% +$457K ﹤0.01% 1958
2019
Q4 		$3.14M Buy
193,477
+94,212
+95% +$2.23M ﹤0.01% 2232
2019
Q3 		$3.47M Sell
99,265
-88
-0.1% -$4.19K ﹤0.01% 2144
2019
Q2 		$5.61M Buy
+99,353
New +$7.15M ﹤0.01% 1919

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Nuveen's ANAB Position: Q2 2026 in Review

Nuveen increased its AnaptysBio (ANAB) stake by 33% in Q2 2026, buying an estimated $6.34M and bringing the position to 420,664 shares worth $28.4M. The position accounts for 0.01% of the portfolio, ranked #1040.

Nuveen first reported a position in ANAB in Q2 2019 and has held it in 29 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

  • Nuveen held 420,664 shares of AnaptysBio worth $28.4M as of Q2 2026.
  • Nuveen bought 104,599 AnaptysBio shares in Q2 2026, an estimated $6.34M.
  • AnaptysBio made up 0.01% of Nuveen's portfolio in Q2 2026, its #1040 holding.
  • Nuveen first reported a position in AnaptysBio in Q2 2019 and has held it in 29 quarters since.
  • 213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.